StockData

VitaSpring Biomedical Co. Ltd. (VSBC) stock

VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 17, 2026Score 4/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $6.58MP/E –Yield –

VitaSpring Biomedical Co. Ltd. reported revenue of $0 for the twelve months to Jul 31, 2026. At the latest close the market valued the company at $6.58M.

Revenue
$0
TTM Q2 2027
Operating income
-$454.86K
TTM Q2 2027
EPS, diluted
$0.00
TTM Q2 2027

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 31, 2026

Valuation

Market cap
$6.58M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$455.64K
EPS, diluted
$0.00
Book value per share
-$0.02
Diluted shares
207M

Trading

Previous close
$0.03
Open
$0.03
Day's range
$0.03 – $0.03
Volume
0

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodVSBCS&P 500DifferenceVSBC per yearS&P 500 per year
1 month+186.5%+0.6%+185.9 pts
3 months+186.5%+3.4%+183.1 pts
Year to date-96.8%+13.3%−110.1 pts
1 year-96.8%+16.6%−113.4 pts
3 years-99.8%+86.4%−186.2 pts-87.4%+23.1%
5 years-99.8%+81.9%−181.6 pts-71.0%+12.7%

Ten years at a glance

Fiscal years 2017 to 2026 and trailing twelve months, USD

Revenue

$0

Gross profit

–

Operating income

-$454.86K

Net income

-$455.64K

EPS, diluted

$0.00

Free cash flow

–
Reported periodTrailing twelve months

About VitaSpring Biomedical

Services-Commercial Physical & Biological Research

VitaSpring Biomedical Co. Ltd. is a development-stage biomedical company dedicated to researching, developing, and commercializing technologies that support wellness, regenerative medicine, and healthy lifestyles. The company concentrates on advancing cellular medical solutions utilizing its proprietary X.msc mesenchymal stem-cell platform and derivative exosome formulations. These technologies are intended for potential applications in tissue repair, skincare, preventive healthcare, and anti-aging. VitaSpring does not currently sell consumer products or therapies, as its offerings remain in early development and require scientific evaluation alongside regulatory clearances. Operating under a business-to-business model, the firm intends to serve institutional and clinical clients through contract cell manufacturing, technology licensing, and research collaborations.

Company profile, executives and history

VitaSpring Biomedical stock: common questions

What is VitaSpring Biomedical's stock price?

VSBC closed at $0.03 on Oct 19, 2026, up 0.00% on the day.

What is VitaSpring Biomedical's market cap?

VitaSpring Biomedical was worth $6.58M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is VSBC's P/E ratio?

VitaSpring Biomedical lost money over the twelve months to Jul 31, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

How much revenue does VitaSpring Biomedical make?

VitaSpring Biomedical reported revenue of $0 for the twelve months to Jul 31, 2026.

Does VitaSpring Biomedical pay a dividend?

No. VitaSpring Biomedical has not paid a cash dividend over the last twelve months.

How has VSBC stock performed over the past year?

Including dividends, VSBC returned -96.8% over the past year, against +16.6% for the S&P 500.

Who are VitaSpring Biomedical's competitors?

Companies most similar to VitaSpring Biomedical by business, industry and size include MXCT, IBAC, BUDZ, ONMD, FOXO.

See a number that looks wrong?